Literature DB >> 1827988

Coronary effects of nicorandil in comparison with nitroglycerin in chronic conscious dogs.

K Hashimoto1, M Kinoshita, Y Ohbayashi.   

Abstract

The effects of nicorandil (0.2 mg/kg, IV) and nitroglycerin (15 micrograms/kg, IV) on large and small coronary arteries were compared in conscious dogs instrumented with ultrasonic crystals and electromagnetic flow meters in the circumflex coronary artery. Nicorandil dilated the large coronary arteries to the same extent, but with a longer duration of action than nitroglycerin. The small coronary arteries dilated for a very short period of time with nitroglycerin, but dilated markedly with nicorandil. The dilatory action of nicorandil on large coronary arteries persisted after the action on the small coronary artery fell to the control value, indicating that the dilatory action on the large coronary arteries is due to the direct relaxing effect on smooth muscle and is not the result of the flow-dependent effect. The measurement of the plasma concentration of nicorandil after incremental infusions of the agent showed that the dilation of the small coronary artery took place at only a very high level (above 200 ng/ml). On the other hand, the large coronary arteries responded to nicorandil at a much lower concentration (about 100 ng/ml, the clinically effective plasma concentration of nicorandil) than the small coronary resistance arteries. In conclusion, whereas nicorandil possesses a dilatory action on both large and small coronary arteries, in a clinical setting, with a daily dosage of 15-30 mg, part of the beneficial effects of nicorandil may be the result of a dilation of the large coronary arteries and may be due to the fact that a coronary steal phenomenon does not occur after nicorandil administration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1827988     DOI: 10.1007/bf03029808

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  35 in total

1.  Effects of anti-anginal agents on cyclical reductions of coronary blood flow.

Authors:  Y Uchida; N Yoshimoto; S Murao
Journal:  Jpn Heart J       Date:  1978-11

2.  Effects of nicorandil on coronary circulation in patients with ischemic heart disease: comparison with nitroglycerin.

Authors:  T Aizawa; K Ogasawara; K Kato
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

Review 3.  Similarity and dissimilarity in the mode and mechanism of action between nicorandil and classical nitrates: an overview.

Authors:  N Taira
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

4.  Effects of 2-nicotinamidoethyl nitrate on smooth muscle cells and on adrenergic transmission in the guinea-pig and porcine mesenteric arteries.

Authors:  T Itoh; K Furukawa; M Kajiwara; K Kitamura; H Suzuki; Y Ito; H Kuriyama
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

5.  A digital sonomicrometer for two-point length and velocity measurements.

Authors:  C A Goodman; F S Castellana
Journal:  Am J Physiol       Date:  1982-10

6.  Relaxing effect of nicorandil (N-2-(hydroxyethyl)-nicotinamide nitrate), a new anti-angina agent, on the isolated vascular smooth muscle.

Authors:  S Shibata; N Satake; T Takagi; F Kerfoot; T K Suh
Journal:  Eur J Pharmacol       Date:  1984-03-23       Impact factor: 4.432

Review 7.  Nicorandil as a hybrid between nitrates and potassium channel activators.

Authors:  N Taira
Journal:  Am J Cardiol       Date:  1989-06-20       Impact factor: 2.778

8.  Pharmacology of the nitrates in angina pectoris.

Authors:  W H Frishman
Journal:  Am J Cardiol       Date:  1985-12-27       Impact factor: 2.778

9.  Comparative efficacy of high-dose versus low-dose nicorandil therapy for chronic stable angina pectoris.

Authors:  M Kinoshita; S Nishikawa; M Sawamura; S Yamaguchi; K Mitsunami; M Itoh; M Motomura; K Bito; I Mashiro; S Kawakita
Journal:  Am J Cardiol       Date:  1986-10-01       Impact factor: 2.778

10.  Pharmacodynamic and metabolism studies on a new coronary vasodilator, N-(2-hydroxyethyl) nicotinamide nitrate (SG-75).

Authors:  K Sakai; Y Ohba; M Akima; H Kamiyama; Y Hinohara; H Nakano
Journal:  Jpn J Pharmacol       Date:  1980-12
View more
  7 in total

1.  Intravenous nicorandil versus adenosine for fractional flow reserve measurement: a crossover, randomized study.

Authors:  Takeshi Nishi; Hideki Kitahara; Yoshihide Fujimoto; Takashi Nakayama; Kengo Nagashima; Hideki Hanaoka; Yoshio Kobayashi
Journal:  Heart Vessels       Date:  2018-06-01       Impact factor: 2.037

2.  Tilisolol hydrochloride dilates coronary arteries through an ATP-sensitive K(+)-channel opening mechanism in dogs.

Authors:  Q Liu; I Nakae; M Takahashi; A Takaoka; M Kinoshita
Journal:  Cardiovasc Drugs Ther       Date:  1996-03       Impact factor: 3.727

3.  The effect of nicorandil on small intestinal ischemia-reperfusion injury in a canine model.

Authors:  Yujin Suto; Kiyohiro Oshima; Kazuhisa Arakawa; Hiroaki Sato; Hodaka Yamazaki; Koshi Matsumoto; Izumi Takeyoshi
Journal:  Dig Dis Sci       Date:  2011-03-01       Impact factor: 3.199

4.  Estimation of coronary flow reserve by intracoronary administration of nicorandil: comparison with intracoronary administration of papaverine.

Authors:  F Inoue; T Hashimoto; S Fujimoto; S Uemura; A Kawamoto; K Dohi
Journal:  Heart Vessels       Date:  1998       Impact factor: 2.037

5.  Mechanism of the vasodilatory action of nicorandil on coronary circulation in dogs.

Authors:  I Nakae; L Quan; K Hashimoto; Y Sugimoto; T Tsutamoto; M Kinoshita
Journal:  Cardiovasc Drugs Ther       Date:  1994-02       Impact factor: 3.727

Review 6.  Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.

Authors:  J Frampton; M M Buckley; A Fitton
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

7.  Nicorandil was an Effective Treatment Option for a Patient with Bland-White-Garland Syndrome.

Authors:  Shun Morishita; Hirofumi Maeba; Kazuya Takehana; Ichiro Shiojima
Journal:  Intern Med       Date:  2017-08-10       Impact factor: 1.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.